This new medical technology is based on the properties of the periosteum, a membrane that covers the bones. It secretes a protein that is key to controlling the diameter of the bone, and therefore its strength: periostin.
A new device for diagnosing bone fragility invented by the HUG and the UNIGE has been approved for marketing in the European Economic Area and Switzerland. This new medical technology is based on the properties of the periosteum, a membrane that covers the bones. It secretes a protein that is key to controlling the diameter of the bone, and therefore its strength: periostin. HUG A new device for diagnosing bone fragility invented by the University Hospitals of Geneva (HUG) and the University of Geneva has been approved for marketing in the European Economic Area and Switzerland. Licensed by the Northern Irish company ProAxsis, it has been launched this summer. The device is based on a new approach to assessing bone quality via blood sampling. This test is much more specific than current techniques and will significantly improve diagnosis and advance the development of new treatments for osteoporosis.
TO READ THIS ARTICLE, CREATE YOUR ACCOUNT
And extend your reading, free of charge and with no commitment.
Your Benefits
- Access to all content
- Receive newsmails for news and jobs
- Post ads
